AUTHORS
Daniel Gao, Apoorva Babu2, Leia Norton3, Matthew Ho, MBBS, PhD4, Luca Paruzzo, MD5, Marie Juzans, PhD6, Zachary Martinez7, Madison Hannan8, Andrew Hughes, MD, PhD9, Scott Canna10, David T. Teachey, MD11, Roddy O'Connor, PhD12, Stephan A Grupp, MD, PhD13, Regina M. Myers, MD14, Joseph Fraietta, PhD15, Caroline Diorio, MD16
AFFILIATIONS
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
10 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
11 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
12 University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
14 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
15 University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction: Immune effector cell–associated hemophagocytic lymphohistiocytosis-like syndrome (IECHS) is an emerging significant toxicity following CAR T-cell therapy characterized by hyperferritinemia and systemic immune dysregulation, temporally distinct from cytokine release syndrome (CRS; PMID: 36906275). Pronounced cytokine dysregulation has been described in IECHS (PMID: 41411617), but the cytokine architecture underlying its onset and progression remains unknown. Unlike CRS, no reliable pre-infusion biomarkers predict the development of IECHS. We performed longitudinal serum proteomic profiling and metabolomic analysis in B-ALL patients treated with co-infusion of CD19- and CD22-directed CART who did and did not develop IECHS to identify preinfusion and longitudinal biomarkers.
Methods: IECHS was graded as per ASTCT. 5400+ serum proteins were measured by proximity extension assay (PEA), using the Olink Explore HT Platform. Protein abundance was reported as normalized protein expression (NPX) values. Differential expression was assessed using linear models and multiple testing correction by the Benjamini–Hochberg method. For exploratory analysis, a cross-validated random forest (1000 trees, class-balanced) ranked proteins by mean decrease in accuracy (MDA). An adjusted P value < 0.05 was considered significant. Serum samples from patients with and without severe IECHS were profiled longitudinally (Day -1, 7, 21, and 28) using semi-quantitative LC-MS-based metabolomics.
Results: We identified a cohort of 14 patients who developed severe (Grade 3+, n=5), minimal (Grade 1-2, n=4) or no IECHS (n=5) following CART19 and CART22 co-infusions (NCT05674175). We performed Olink proteomic profiling on longitudinal samples ranging from pre-infusion to day 279 (N=89 samples). Peak expansion of CART19 occurred at day 7 (Range: 7-21) and CART22 at day 21 (Range: 21-28). Median IECHS onset occurred on day 21 (Range: 14-90). Median duration of IECHS was 25 days and 43 days in patients with minimal vs. severe IECHS respectively.
At preinfusion, there were 32 differentially expressed proteins in patients with IECHS compared to patients without IECHS. Combined with a random forest classification of patients with and without IECHS, FBXL5 emerged as a top ranked candidate (MDA: 0.723). FBXL5 governs cellular iron metabolism, favoring ferritin-mediated iron storage under iron-replete conditions (PMID: 32126207). Lower FBXL5 in IECHS patients suggests dysfunctional iron sensing and homeostasis. FBXL5 abundance stratified patients according to IECHS severity, segregating minimal (median = -0.115, p = 0.016, Wilcoxon), severe (median = -2.17, p = 0.012, Wilcoxon), and combined severity (median = -0.31, p = 0.003, Wilcoxon) cases from those without IECHS (median = 1.68). We used metabolic profiling to further characterize differences in the metabolic environment between patients who did and did not develop IECHS. IECHS patients had a distinct metabolic signature at preinfusion, marked by depleted very long chain fatty acids and elevated C8 acylcarnitine. This evolved into hepatic/urea cycle strain, and tryptophan depletion accompanied by kynurenine elevation consistent with IDO induction at later timepoints.
In this cohort, we found that IFNG did not discriminate between patients with severe IECHS (AUC/Day: 2.6 ± 0.974) and patients without IECHS (AUC/Day: 1.55 ± 1.04; p = 0.531). Comparing IECHS and non-IECHS patients across timepoint- and event-based groupings revealed enrichment for serum proteins associated with T-cell activation and proliferation at IECHS onset. Key regulators of this process include LCK, BATF, GATA3, and FOS. LCK, which phosphorylates the TCR complex after antigen engagement, increased through IECHS onset and declined thereafter, distinguishing severe (AUC/Day: 2.28 ± 0.615) from non-IECHS (AUC/Day: 0.587 ± 0.383) patients over time (p = 0.037, Wilcoxon).
Conclusion: Using serum proteomic profiling, we nominate candidate preinfusion and longitudinal biomarkers and provide new insights into IECHS pathogenesis. We identified FBXL5 as a pre-infusion biomarker and LCK as a longitudinal biomarker that stratified patients according to subsequent IECHS status. Using metabolic profiling we identified significant serum metabolic differences in patients who developed severe IECHS, beginning prior to infusion. Future studies will validate the mechanistic role of these proteins in the initiation and progression of IECHS.
DISCLOSURES
Daniel Gao: No relevant conflicts of interest to declare.